Sign In
Buy VERU
$2.25
-0.100 (-4.26%)
At Close: Jun 03, 2026
Veru Inc. (VERU) Q2 2026 Earnings Call Prepared Remarks Transcript
11:50am, Wednesday, 13'th May 2026
Veru Inc. (VERU) Q2 2026 Earnings Call Prepared Remarks Transcript
Veru Reports Fiscal 2026 Second Quarter Financial Results and Phase 2b PLATEAU Clinical Trial Progress
06:30am, Wednesday, 13'th May 2026
--Phase 2b PLATEAU clinical study evaluating enobosarm + semaglutide is actively enrolling and on track for i nterim analysis first quarter calendar year 2027 —
Veru to Report Fiscal 2026 Second Quarter Financial Results on May 13th
08:30am, Wednesday, 06'th May 2026
MIAMI, FL, May 06, 2026 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic an
Veru (NASDAQ:VERU) Share Price Crosses Below 200 Day Moving Average – Here’s Why
03:54am, Friday, 24'th Apr 2026
Veru Inc. (NASDAQ: VERU - Get Free Report)'s stock price crossed below its 200-day moving average during trading on Thursday. The stock has a 200-day moving average of $2.64 and traded as low as $2.28
Veru (NASDAQ:VERU) Stock Passes Below 200 Day Moving Average – Should You Sell?
03:19am, Thursday, 16'th Apr 2026
Veru Inc. (NASDAQ: VERU - Get Free Report) shares passed below its 200-day moving average during trading on Wednesday. The stock has a 200-day moving average of $2.69 and traded as low as $2.39. Veru
Veru (NASDAQ:VERU) Shares Cross Below 200 Day Moving Average – Here’s Why
02:40am, Friday, 27'th Mar 2026
Veru Inc. (NASDAQ: VERU - Get Free Report)'s stock price passed below its 200-day moving average during trading on Thursday. The stock has a 200-day moving average of $2.81 and traded as low as $2.19.
-- The Phase 2b study to assess enobosarm's ability to preserve lean mass, physical function, and bone as well as burn more fat to produce greater quality and quantity of weight loss in older patients
Veru Inc. (VERU) Q1 2026 Earnings Call Transcript
01:54pm, Wednesday, 11'th Feb 2026
Veru Inc. (VERU) Q1 2026 Earnings Call Transcript
Flora Growth (NASDAQ:FLGC) and Veru (NASDAQ:VERU) Financial Review
01:32am, Sunday, 08'th Feb 2026
Veru (NASDAQ: VERU - Get Free Report) and Flora Growth (NASDAQ: FLGC - Get Free Report) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based
Veru to Report Fiscal 2026 First Quarter Financial Results on February 11th
08:30am, Wednesday, 04'th Feb 2026
MIAMI, FL, Feb. 04, 2026 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic a
Veru Inc. (VERU) Q4 2025 Earnings Call Transcript
11:59am, Wednesday, 17'th Dec 2025
Veru Inc. (VERU) Q4 2025 Earnings Call Transcript
Veru Reports Fiscal Year 2025 Financial Results and Clinical Program Progress
06:30am, Wednesday, 17'th Dec 2025
MIAMI, FL, Dec. 17, 2025 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic a
Veru (NASDAQ:VERU) Share Price Crosses Below Two Hundred Day Moving Average – Here’s Why
05:30am, Tuesday, 16'th Dec 2025
Veru Inc. (NASDAQ: VERU - Get Free Report) shares passed below its 200-day moving average during trading on Monday. The stock has a 200-day moving average of $4.16 and traded as low as $2.38. Veru sha
Veru to Report Fiscal Year 2025 Financial Results on December 17th
08:30am, Wednesday, 10'th Dec 2025
MIAMI, FL, Dec. 10, 2025 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic a
Veru to Present Two Abstracts at ObesityWeek 2025
08:30am, Friday, 31'st Oct 2025
MIAMI, FL, Oct. 31, 2025 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic a
